Harry Alcorn
Chief Scientific Officer
Dr. Harry Alcorn is an integral part of the Elixia team, adding a rich tapestry of both scientific acumen and operational insight borne of over two decades of industry experience. Harry’s unique capability to seamlessly integrate operational strategy with a scientific approach is key to maintaining Elixia’s reputation as a forward-thinking, innovative, and reproducible trial management organization.
Serving as the head of operations in the Early Phase Clinical Trials Division of Elixia, Harry’s leadership is essential in driving our unique position as the only niche-focused clinical trials company conducting Phase I-IV trials. His profound expertise is instrumental in maintaining the company’s commitment to excellence, reliability, and innovation.
Harry joined Elixia in 2023, bringing with him a mission to create a comprehensive ecosystem of clinical trial services offered to the industry. Guided by this vision, he has been at the helm of the Phase I Division, overseeing a range of initiatives and ensuring the delivery of top-tier services.
Under Harry’s stewardship, Elixia continues to disrupt the clinical trial landscape, setting new standards and paving the way for future advancements. His unwavering dedication to improving patient outcomes, coupled with a deep commitment to scientific rigor, perfectly mirrors Elixia’s ethos.
Harry’s robust experience, passion for innovation, and strategic leadership are pivotal in Elixia’s pursuit to revolutionize the way clinical trials are conducted. His work is not just a testament to his individual expertise, but also a reflection of the collective drive of Elixia to make a profound impact on the lives of patients across the globe.
